Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Sulfapyridine is a sulfonamide antibiotic and anti-inflammatory small molecule that was historically used to treat dermatitis herpetiformis (Duhring’s disease), benign mucous membrane pemphigoid, pyoderma gangrenosum, rheumatoid arthritis, ulcerative colitis, Crohn’s disease, and systemic lupus erythematosus[1][2][5]. Its primary mechanism of action is as a competitive inhibitor of the bacterial enzyme dihydropteroate synthase, which blocks folic acid synthesis in susceptible bacteria by interfering with the processing of para-aminobenzoic acid (PABA)[2][7]. Sulfapyridine is also a major metabolite of sulfasalazine. It has been discontinued for marketing in many regions due to safety concerns and the availability of better alternatives[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on sulfapyridine.